Jocelyn Grosse

Jocelyn Grosse

Auto-generated profile, based on publicly available information

Jocelyn Grosse

Laboratory of Behavioral Genetics, Brain Mind Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2022 in Science Advances
Verified
Journal Article
Open access
IZIoannis Zalachoras
Ioannis Zalachoras
SASimone Astori
Simone Astori
MMMandy Meijer
Mandy Meijer
JGJocelyn Grosse
Jocelyn Grosse
OZOlivia Zanoletti
Olivia Zanoletti
CSCarmen Sandi
Carmen Sandi
Individuals frequently differ in their behavioral and cognitive responses to stress. However, whether motivation is differently affected by acute stress in different individuals remains to be established. By exploiting natural variation in trait anxiety in outbred Wistar rats, we show that acute stress facilitates effort-related motivation in low anxious animals, while dampening effort in high anxious ones. This model allowed us to address the mechanisms underlying acute stress–induced differences in motivated behavior. We show that CRHR1 expression levels in dopamine neurons of the ventral tegmental area (VTA)—a neuronal type implicated in the regulation of motivation—depend on animals’ anxiety, and these differences in CRHR1 expression levels explain the divergent effects of stress on both effortful behavior and the functioning of mesolimbic DA neurons. These findings highlight CRHR1 in VTA DA neurons—whose levels vary with individuals’ anxiety—as a switching mechanism determining whether acute stress facilitates or dampens motivation.

4 March 2022 in Science Advances
Verified
Journal Article
Open access
LMLaia Morató
Laia Morató
SASimone Astori
Simone Astori
IZIoannis Zalachoras
Ioannis Zalachoras
JRJoão Rodrigues
João Rodrigues
SGSriparna Ghosal
Sriparna Ghosal
CSCarmen Sandi
Carmen Sandi
Obesity is frequently associated with impairments in the social domain, and stress at puberty can lead to long-lasting changes in visceral fat deposition and in social behaviors. However, whether stress-induced changes in adipose tissue can affect fat-to-brain signaling, thereby orchestrating behavioral changes, remains unknown. We found that peripubertally stressed male—but not female—mice exhibit concomitant increased adiposity and sociability deficits. We show that reduced levels of the adipokine nicotinamide phosphoribosyltransferase (NAMPT) in fat and its extracellular form eNAMPT in blood contribute to lifelong reductions in sociability induced by peripubertal stress. By using a series of adipose tissue and brain region–specific loss- and gain-of-function approaches, we implicate impaired nicotinamide adenine dinucleotide (NAD + )/SIRT1 pathway in the nucleus accumbens. Impairments in sociability and accumbal neuronal excitability are prevented by normalization of eNAMPT levels or treatment with nicotinamide mononucleotide (NMN), a NAD + -boosting compound. We propose NAD + boosters to treat social deficits of early life stress origin.

23 September 2023 in Biological Psychiatry
Verified
Journal Article
Open access
SMSilvia Monari
Silvia Monari
ISIsabelle Guillot de Suduiraut
Isabelle Guillot de Suduiraut
JGJocelyn Grosse
Jocelyn Grosse
OZOlivia Zanoletti
Olivia Zanoletti
SWSophie E. Walker
Sophie E. Walker
CSCarmen Sandi
Carmen Sandi
Understanding why only a subset of trauma-exposed individuals develop posttraumatic stress disorder (PTSD) is critical for advancing clinical strategies. A few behavioral (deficits in fear extinction) and biological (blunted glucocorticoid levels, small hippocampal size, and rapid-eye movement sleep (REMS) disturbances) traits have been identified as potential vulnerability factors. However, whether and to what extent these traits are interrelated and whether one of them could causally engender the others are not known. In a genetically selected rat model of reduced corticosterone responsiveness to stress, we explored PTSD-related biobehavioral traits using ex vivo magnetic resonance imaging, cued fear conditioning, and polysomnographic recordings combined with in vivo photometric measurements. We showed that genetic selection for blunted glucocorticoid responsiveness leads to a correlated multitrait response, including impaired fear extinction -observed in males but not in females-, small hippocampal volume, and REMS disturbances, supporting their interrelatedness. Fear extinction deficits and concomitant disruptions in REMS could be normalized through postextinction corticosterone administration, causally implicating glucocorticoid deficiency in two core PTSD-related risk factors and manifestations. Furthermore, reduced REMS was accompanied by higher norepinephrine levels in the hippocampal dentate gyrus that were also reverted by postextinction corticosterone treatment. Our results indicate a predominant role for glucocorticoid deficiency over the contribution of reduced hippocampal volume in engendering both REMS alterations and associated deficits in fear extinction consolidation, and causally implicate blunted glucocorticoids in sustaining neurophysiological disturbances leading to fear extinction deficits.

15 January 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LDLara Duran-Trio
Lara Duran-Trio
GFGabriella Fernandes-Pires
Gabriella Fernandes-Pires
DSDunja Simicic
Dunja Simicic
JGJocelyn Grosse
Jocelyn Grosse
CRClothilde Roux-Petronelli
Clothilde Roux-Petronelli
OBOlivier Braissant
Olivier Braissant
Creatine is an organic compound used as fast phosphate energy buffer to recycle ATP, important in tissues with high energy demand such as muscle or brain. Creatine is taken from the diet or endogenously synthetized by the enzymes AGAT and GAMT, and specifically taken up by the transporter SLC6A8. Deficit in the endogenous synthesis or in the transport leads to Cerebral Creatine Deficiency Syndromes (CCDS). CCDS are characterized by brain creatine deficiency, intellectual disability with severe speech delay, behavioral troubles such as attention deficits and/or autistic features, and epilepsy. Among CCDS, the X-linked creatine transporter deficiency (CTD) is the most prevalent with no efficient treatment so far. Different mouse models of CTD were generated by doing long deletions in the Slc6a8 gene showing reduced brain creatine and cognitive deficiencies or impaired motor function. We present a new knock-in (KI) rat model of CTD holding an identical point mutation found in patients with reported lack of transporter activity. KI males showed brain creatine deficiency, increased urinary creatine/creatinine ratio, cognitive deficits and autistic-like traits. The Slc6a8Y389C KI rat fairly enriches the spectrum of CTD models and provides new data about the pathology, being the first animal model of CTD carrying a point mutation.

1 September 2016 in eneuro
Verified
Journal Article
Open access
PDF file
FHFiona Hollis
Fiona Hollis
YSYannick Sevelinges
Yannick Sevelinges
JGJocelyn Grosse
Jocelyn Grosse
OZOlivia Zanoletti
Olivia Zanoletti
CSCarmen Sandi
Carmen Sandi
Several animal and clinical studies have highlighted the ineffectiveness of fear extinction sessions delivered shortly after trauma exposure. This phenomenon, termed the immediate extinction deficit, refers to situations in which extinction programs applied shortly after fear conditioning may result in the reduction of fear behaviors (in rodents, frequently measured as freezing responses to the conditioned cue) during extinction training, but failure to consolidate this reduction in the long term. The molecular mechanisms driving this immediate extinction resistance remain unclear. Here we present evidence for the involvement of the corticotropin releasing factor (CRF) system in the basolateral amygdala (BLA) in male Wistar rats. Intra-BLA microinfusion of the CRFR1antagonist NBI30775 enhances extinction recall, whereas administration of the CRF agonist CRF6–33before delayed extinction disrupts recall of extinction. We link the immediate fear extinction deficit with dephosphorylation of GluA1 glutamate receptors at Ser845and enhanced activity of the protein phosphatase calcineurin in the BLA. Their reversal after treatment with the CRFR1antagonist indicates their dependence on CRFR1actions. These findings can have important implications for the improvement of therapeutic approaches to trauma, as well as furthering our understanding of the neurobiological mechanisms underlying fear-related disorders.

22 December 2021 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
LDLara Duran‐Trio
Lara Duran‐Trio
GFGabriella Fernandes‐Pires
Gabriella Fernandes‐Pires
JGJocelyn Grosse
Jocelyn Grosse
ISInes Soro‐Arnaiz
Ines Soro‐Arnaiz
CRClothilde Roux‐Petronelli
Clothilde Roux‐Petronelli
OBOlivier Braissant
Olivier Braissant
Creatine (Cr) is a nitrogenous organic acid and plays roles such as fast phosphate energy buffer to replenish ATP, osmolyte, antioxidant, neuromodulator, and as a compound with anabolic and ergogenic properties in muscle. Cr is taken from the diet or endogenously synthetized by the enzymes arginine:glycine amidinotransferase and guanidinoacetate methyltransferase, and specifically taken up by the transporter SLC6A8. Loss‐of‐function mutations in the genes encoding for the enzymes or the transporter cause creatine deficiency syndromes (CDS). CDS are characterized by brain Cr deficiency, intellectual disability with severe speech delay, behavioral troubles, epilepsy, and motor dysfunction. Among CDS, the X‐linked Cr transporter deficiency (CTD) is the most prevalent with no efficient treatment so far. Different animal models of CTD show reduced brain Cr levels, cognitive deficiencies, and together they cover other traits similar to those of patients. However, motor function was poorly explored in CTD models, and some controversies in the phenotype exist in comparison with CTD patients. Our recently described Slc6a8Y389C knock‐in rat model of CTD showed mild impaired motor function, morphological alterations in cerebellum, reduced muscular mass, Cr deficiency, and increased guanidinoacetate content in muscle, although no consistent signs of muscle atrophy. Our results indicate that such motor dysfunction co‐occurred with both nervous and muscle dysfunctions, suggesting that muscle strength and performance as well as neuronal connectivity might be affected by this Cr deficiency in muscle and brain.